Therapeutic potential of targeting the complement cascade in critical care medicine

被引：38

作者：

Bhole, D ^{[1
]}

Stahl, GL ^{[1
]}

机构：

[1] Harvard Univ, Ctr Expt Therapeut & Reperfus Injury, Sch Med,Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA

来源：

CRITICAL CARE MEDICINE | 2003年 / 31卷 / 01期

关键词：

cardiopulmonary bypass; sepsis; inflammation; C5a; mannose binding protein; C3a; C3; C1q; pexelizumab; TP-10;

D O I：

10.1097/00003246-200301001-00014

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Caring for the critical care patient involves many different areas of clinical expertise and serves a diverse patient population. Novel therapeutics for the critically ill must be approached with caution, because the underlying molecular mechanisms of the disease process for several commonly seen types of patients (i.e., sepsis, shock, ischemia/reperfusion) are not fully understood. A potentially new and advancing area of therapeutics that may hold promise for the critically ill. is inhibition of the complement system. Various novel complement inhibitors are being developed and several are in clinical trials. The advancement of this novel area of therapeutics may one day aid the clinician by providing several different complement inhibitors/antagonists for controlling complement activation or its biologically active mediators.

引用

页码：S97 / S104

页数：8

共 83 条

[1] INCREASED SUSCEPTIBILITY TO INFECTION ASSOCIATED WITH ABNORMALITIES OF COMPLEMENT-MEDIATED FUNCTIONS AND OF THIRD COMPONENT OF COMPLEMENT (C3) [J].